Sonya C. Chapman

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 261 citations

Medicine, Oncology, Pharmacology +16

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun et al. · Clinical Cancer Research · 2020 · 198 citations

Medicine, Oncology, Pharmacology +17

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

Hope S. Rugo, Peter Kabos, Julia Beck et al. · npj Breast Cancer · 2022 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Karen A. Autio, Christopher A. Klebanoff, David Schaer et al. · Clinical Cancer Research · 2020 · 67 citations · Full text

Medicine, Immunology, Pharmacology +17

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Gerald S. Falchook, Marc Peeters, Sylvie Rottey et al. · Investigational New Drugs · 2021 · 58 citations

Medicine, Oncology, Pharmacology +15